Invivyd, Inc. (NASDAQ:IVVD)
| Market Cap | 294.46M-18.1% |
| Revenue (ttm) | 58.37M+26.3% |
| Net Income | -107.33M+2.5% |
| EPS | -0.39+57.1% |
| Shares Out | 294.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,515,089 |
| Open | 0.83 |
| Previous Close | 0.76 |
| Day's Range | 0.82 - 1.05 |
| 52-Week Range | 0.53 - 3.07 |
| Beta | 0.71 |
| Analysts | Buy |
| Price Target | 9.50(+850.48%) |
| Earnings Date | Nov 5, 2026 |
Invivyd, Inc. has a live Insider Score.
Scored on 0 qualifying trades from 0 insiders in the last 90 days.
About IVVD
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$IVVD stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in IVVD holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IVVD's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IVVD Estimated quarterly lobbying spending
Source: U.S. Senate LDA
IVVD Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| VYD2311 | $20.35M | 85.68% |
| Other income, net | $1.43M | 6.01% |
| Cost of product revenue | $1.27M | 5.36% |
| Pemivibart | $265.00K | 1.12% |
| VMS063 | $182.00K | 0.77% |
| Early-stage programs | $175.00K | 0.74% |
| VBY329 | $80.00K | 0.34% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New IVVD patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IVVD from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in IVVD
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $7.43M |
| VXFVanguard Extended Market ETF | $2.46M |
| VTWOVanguard Russell 2000 ETF | $1.16M |
| BBCVirtus Biotech Clinical Trials ETF | $311.28K |
| VTWVVanguard Russell 2000 Value ETF | $186.14K |
| RSSLGlobal X - Russell 2000 ETF | $77.14K |
Estimated from each fund’s disclosed top holdings × AUM
IVVD Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from IVVD’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score